These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15676040)

  • 1. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.
    Jullien V; Tréluyer JM; Chappuy H; Dimet J; Rey E; Dupin N; Salmon D; Pons G; Urien S
    Br J Clin Pharmacol; 2005 Feb; 59(2):183-8. PubMed ID: 15676040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.
    Jullien V; Urien S; Chappuy H; Dimet J; Rey E; Pons G; Blanche S; Tréluyer JM
    J Clin Pharmacol; 2005 Mar; 45(3):257-64. PubMed ID: 15703361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
    Jullien V; Tréluyer JM; Rey E; Jaffray P; Krivine A; Moachon L; Lillo-Le Louet A; Lescoat A; Dupin N; Salmon D; Pons G; Urien S
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3361-6. PubMed ID: 16048948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
    Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
    Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.
    Capparelli EV; Letendre SL; Ellis RJ; Patel P; Holland D; McCutchan JA
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2504-6. PubMed ID: 15917556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pregnancy on abacavir pharmacokinetics.
    Best BM; Mirochnick M; Capparelli EV; Stek A; Burchett SK; Holland DT; Read JS; Smith E; Hu C; Spector SA; Connor JD;
    AIDS; 2006 Feb; 20(4):553-60. PubMed ID: 16470119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes.
    Archary M; Mcllleron H; Bobat R; LaRussa P; Sibaya T; Wiesner L; Hennig S
    Br J Clin Pharmacol; 2019 Sep; 85(9):2066-2075. PubMed ID: 31141195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
    Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function.
    Izzedine H; Launay-Vacher V; Aymard G; Legrand M; Deray G
    Nephron; 2001 Sep; 89(1):62-7. PubMed ID: 11528234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.
    Jullien V; Raïs A; Urien S; Dimet J; Delaugerre C; Bouillon-Pichault M; Rey E; Pons G; Blanche S; Tréluyer JM
    Br J Clin Pharmacol; 2007 Jul; 64(1):105-9. PubMed ID: 17324223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
    Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of abacavir in infants, toddlers and children.
    Zhao W; Piana C; Danhof M; Burger D; Della Pasqua O; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2013 Jun; 75(6):1525-35. PubMed ID: 23126277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
    Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years.
    Jullien V; Urien S; Hirt D; Delaugerre C; Rey E; Teglas JP; Vaz P; Rouzioux C; Chaix ML; Macassa E; Firtion G; Pons G; Blanche S; Tréluyer JM
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3548-55. PubMed ID: 16940058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the pharmacokinetics of abacavir.
    Yuen GJ; Weller S; Pakes GE
    Clin Pharmacokinet; 2008; 47(6):351-71. PubMed ID: 18479171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
    Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
    McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.
    Weller S; Radomski KM; Lou Y; Stein DS
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2052-60. PubMed ID: 10898675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.